Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738200 | 0.79 | SIGMAR1 (0.36) | SIGMAR1OPRM1 | |
| SCHEMBL738548 | 0.78 | FASN (0.41) | SIGMAR1OPRM1 | |
| SCHEMBL736998 | 0.78 | SIGMAR1 (0.32) | SIGMAR1 | |
| SCHEMBL12832387 | 0.77 | SIGMAR1 (0.47) | SIGMAR1CRBNOPRM1 | |
| Hydrochloric Acid SCHEMBL15534708 | 0.77 | SIGMAR1 (0.32) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL14720614 | 0.77 | FASN (0.40) | SIGMAR1OPRM1 | |
| SCHEMBL736814 | 0.75 | FASN (0.43) | — | |
| SCHEMBL737334 | 0.75 | — | — | |
| SCHEMBL737004 | 0.74 | SIGMAR1 (0.33) | SIGMAR1OPRM1 | |
| SCHEMBL11238139 | 0.74 | PIK3CD (0.40) | SIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| WO-2017060873-A1 | SUBSTITUTED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXYLIC ACIDS AND THEIR USE | AbbVie S.à.r.l. (LU) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060873-A1 | SUBSTITUTED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXYLIC ACIDS AND THEIR USE | AbbVie S.à.r.l. (LU) | 2017-04-13 | — | — | WO | disclosed |
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-4353901-A | HYPERTENSION, CONGESTIVE HEART FAILURE, ARRHYTHMIAMIGRAINE, VASOSPASTIC DISORDERS, ASTHMA | SYNTEX (U.S.A.) INC. (US) | 1982-10-12 | — | — | US | disclosed |
| US-4353900-A | HYPOTENSIVE, ANTIARRHYTHMIA, CARDIOTONIC, VASODILATORS | SYNTEX (U.S.A.) INC. (US) | 1982-10-12 | — | — | US | disclosed |
| EP-0061333-A1 | 9-(2-(3-Indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones | SYNTEX (U.S.A.) INC. (US) | 1982-09-29 | — | — | EP | disclosed |
| US-4332804-A | TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, ARRHYTHMIA, MIGRAINE, VASOSPASTIC DISORDERS AND ASTHMA | SYNTEX (U.S.A.) INC. (US) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | SIGMAR1 11/4885CRBN 3434/4885OPRM1 15/4885 |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | CFTR, CHRM3, P2RY1 | SIGMAR1 1529/4885CRBN 3743/4885OPRM1 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.